Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CO NYSE:CORBF NASDAQ:MRAI NASDAQ:ZVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGlobal Cord Blood$1.05$0.98$2.03▼$5.50$127.63M0.16216,519 shs113 shsCORBFGlobal Cord Blood$1.05$0.97$0.25▼$1.75$127.63M-0.692,256 shs113 shsMRAIMarpai$1.25$1.36$0.43▼$1.68$21.59M4.6616,885 shs662 shsZVRAZevra Therapeutics$8.02-2.4%$10.55$6.19▼$13.16$448.74M1.56772,214 shs780,849 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGlobal Cord Blood0.00%0.00%-22.22%-11.39%-30.00%CORBFGlobal Cord Blood0.00%0.00%-22.22%-16.00%-30.00%MRAIMarpai-2.34%-9.42%-6.72%-10.07%+129.86%ZVRAZevra Therapeutics-1.44%-9.78%-31.70%-12.47%+13.55%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGlobal Cord Blood$1.05$0.98$2.03▼$5.50$127.63M0.16216,519 shs113 shsCORBFGlobal Cord Blood$1.05$0.97$0.25▼$1.75$127.63M-0.692,256 shs113 shsMRAIMarpai$1.25$1.36$0.43▼$1.68$21.59M4.6616,885 shs662 shsZVRAZevra Therapeutics$8.02-2.4%$10.55$6.19▼$13.16$448.74M1.56772,214 shs780,849 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGlobal Cord Blood0.00%0.00%-22.22%-11.39%-30.00%CORBFGlobal Cord Blood0.00%0.00%-22.22%-16.00%-30.00%MRAIMarpai-2.34%-9.42%-6.72%-10.07%+129.86%ZVRAZevra Therapeutics-1.44%-9.78%-31.70%-12.47%+13.55%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOGlobal Cord Blood 0.00N/AN/AN/ACORBFGlobal Cord Blood 0.00N/AN/AN/AMRAIMarpai 0.00N/AN/AN/AZVRAZevra Therapeutics 2.89Moderate Buy$23.71195.87% UpsideCurrent Analyst Ratings BreakdownLatest CO, CORBF, MRAI, and ZVRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025ZVRAZevra TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/13/2025ZVRAZevra TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform8/13/2025ZVRAZevra TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$19.00 ➝ $18.007/10/2025ZVRAZevra TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$25.00 ➝ $29.007/2/2025ZVRAZevra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$26.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOGlobal Cord Blood$1.24B0.10$0.25 per share4.19$6.34 per share0.17CORBFGlobal Cord Blood$196.12M0.65$0.75 per share1.40N/A∞MRAIMarpai$34.87M0.62N/AN/A($1.72) per share-0.73ZVRAZevra Therapeutics$62.02M7.25N/AN/A$0.74 per share10.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOGlobal Cord Blood$79.04M$0.641.64∞N/AN/AN/AN/AN/ACORBFGlobal Cord Blood$79.04MN/A0.00∞N/AN/AN/AN/AN/AMRAIMarpai-$28.75M-$0.87N/A∞N/A-85.70%N/A-100.23%11/11/2025 (Estimated)ZVRAZevra Therapeutics-$105.51M-$0.21N/A40.08N/A4.33%-112.40%-37.67%11/11/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOGlobal Cord Blood$0.087.62%N/A12.50%N/ACORBFGlobal Cord BloodN/AN/AN/AN/AN/AMRAIMarpaiN/AN/AN/AN/AN/AZVRAZevra TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOGlobal Cord BloodN/AN/AN/ACORBFGlobal Cord BloodN/AN/AN/AMRAIMarpaiN/A0.820.82ZVRAZevra Therapeutics0.527.857.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOGlobal Cord BloodN/ACORBFGlobal Cord BloodN/AMRAIMarpai49.75%ZVRAZevra Therapeutics35.03%Insider OwnershipCompanyInsider OwnershipCOGlobal Cord Blood0.50%CORBFGlobal Cord Blood0.50%MRAIMarpai46.10%ZVRAZevra Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOGlobal Cord Blood1,202121.55 millionN/ANo DataCORBFGlobal Cord Blood1,200121.55 millionN/ANot OptionableMRAIMarpai15017.27 million5.61 millionNo DataZVRAZevra Therapeutics2056.14 million54.79 millionOptionableCO, CORBF, MRAI, and ZVRA HeadlinesRecent News About These CompaniesZevra Therapeutics, Inc. (NASDAQ:ZVRA) Sees Large Increase in Short InterestSeptember 9 at 2:53 AM | marketbeat.comZevra Therapeutics, Inc. $ZVRA Stock Holdings Trimmed by Adage Capital Partners GP L.L.C.September 7 at 5:13 AM | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $23.71 Consensus Target Price from AnalystsSeptember 6, 2025 | americanbankingnews.comZevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)September 4, 2025 | globenewswire.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 4, 2025 | marketbeat.comZevra Therapeutics, Inc. $ZVRA Shares Sold by Nantahala Capital Management LLCSeptember 3, 2025 | marketbeat.comRetirement Planning Co of New England Inc. Has $4.12 Million Stock Holdings in Zevra Therapeutics, Inc. $ZVRASeptember 2, 2025 | marketbeat.comWellington Management Group LLP Purchases New Shares in Zevra Therapeutics, Inc. $ZVRASeptember 2, 2025 | marketbeat.comVelan Capital Investment Management LP Increases Stake in Zevra Therapeutics, Inc. $ZVRAAugust 31, 2025 | marketbeat.comZevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)August 28, 2025 | globenewswire.comZevra Therapeutics, Inc. $ZVRA Holdings Boosted by Stonepine Capital Management LLCAugust 26, 2025 | marketbeat.comZevra Therapeutics to Participate at Upcoming Investor Conferences in SeptemberAugust 26, 2025 | globenewswire.comZacks Research Downgrades Zevra Therapeutics (NASDAQ:ZVRA) to HoldAugust 22, 2025 | marketbeat.comZevra Therapeutics rumor highlighted in Betaville blogAugust 21, 2025 | msn.comZevra Therapeutics gains amid takeover speculationAugust 21, 2025 | msn.comZevra Therapeutics (NASDAQ:ZVRA) Director John Bode Buys 5,000 SharesAugust 21, 2025 | insidertrades.comZevra Therapeutics (NASDAQ:ZVRA) Stock Price Up 4.4% - Should You Buy?August 17, 2025 | marketbeat.comCantor Fitzgerald Brokers Lower Earnings Estimates for ZVRAAugust 17, 2025 | marketbeat.comEquities Analysts Offer Predictions for ZVRA Q3 EarningsAugust 17, 2025 | marketbeat.comQ3 EPS Forecast for Zevra Therapeutics Increased by AnalystAugust 17, 2025 | marketbeat.comHC Wainwright Has Bearish Estimate for ZVRA FY2027 EarningsAugust 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025The Case for Buying NVIDIA Stock Ahead of the Robotics SurgeBy Thomas Hughes | August 20, 2025IBM: The Last Time This Happened, the Stock Rallied 35%By Sam Quirke | August 12, 2025Can AI Defense Contracts Push Palantir Shares Higher?By Chris Markoch | August 19, 2025CO, CORBF, MRAI, and ZVRA Company DescriptionsGlobal Cord Blood NYSE:CO$1.05 0.00 (0.00%) As of 09/9/2025Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants. Global Cord Blood was founded on January 17, 2008 and is headquartered in Hong Kong.Global Cord Blood NYSE:CORBF$1.05 0.00 (0.00%) As of 09/9/2025Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.Marpai NASDAQ:MRAI$1.25 0.00 (0.00%) As of 12:40 PM EasternMarpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, bill review and cost containment services. Marpai, Inc. was incorporated in 2021 and is based in Tampa, Florida.Zevra Therapeutics NASDAQ:ZVRA$8.02 -0.20 (-2.38%) As of 01:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Beyond DIY: Home Depot's Conquest of the Professional Market Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
